{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T09:20:45Z","timestamp":1786267245259,"version":"build-2736575974"},"reference-count":43,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002873","name":"Chulalongkorn University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002873","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002873","name":"Chulalongkorn University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002873","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.vaccine.2022.04.067","type":"journal-article","created":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T07:25:10Z","timestamp":1651476310000},"page":"3320-3329","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac"],"prefix":"10.1016","volume":"40","author":[{"given":"Rapisa","family":"Nantanee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puneyavee","family":"Aikphaibul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peera","family":"Jaru-Ampornpan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pimpayao","family":"Sodsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orawan","family":"Himananto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuangtip","family":"Theerawit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiratchaya","family":"Sophonphan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Punyot","family":"Tovichayathamrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasama","family":"Manothummetha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tysdi","family":"Laohasereekul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narin","family":"Hiransuthikul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nattiya","family":"Hirankarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanyawee","family":"Puthanakit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.04.067_b0005","unstructured":"World Health Organization. WHO Coronavirus (COVID-19) Dashboard [Available from: https:\/\/covid19.who.int\/. Accessed date 28 November, 2021."},{"issue":"10","key":"10.1016\/j.vaccine.2022.04.067_b0010","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2107715","article-title":"Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile","volume":"385","author":"Jara","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.04.067_b0015","first-page":"100025","article-title":"Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study","volume":"1","author":"Hitchings","year":"2021","journal-title":"Lancet Reg Health Am"},{"issue":"10","key":"10.1016\/j.vaccine.2022.04.067_b0020","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S1473-3099(21)00568-5","article-title":"CoronaVac induces lower neutralising activity against variants of concern than natural infection","volume":"21","author":"Vacharathit","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"10303","key":"10.1016\/j.vaccine.2022.04.067_b0025","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S0140-6736(21)01694-9","article-title":"Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial","volume":"398","author":"Liu","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.04.067_b0030","doi-asserted-by":"crossref","unstructured":"Benning L, Tollner M, Hidmark A, Schaier M, Nusshag C, Kalble F, et al. Heterologous ChAdOx1 nCoV-19\/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses among Health Care Workers. Vaccines (Basel) 2021;9. https:\/\/doi.org\/10.3390\/vaccines9080857.","DOI":"10.3390\/vaccines9080857"},{"key":"10.1016\/j.vaccine.2022.04.067_b0035","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.2147\/RMHP.S309707","article-title":"Intradermal Vaccination: A Potential Tool in the Battle Against the COVID-19 Pandemic?","volume":"14","author":"Migliore","year":"2021","journal-title":"Risk Manag Healthc Policy"},{"issue":"3","key":"10.1016\/j.vaccine.2022.04.067_b0040","doi-asserted-by":"crossref","first-page":"534","DOI":"10.3390\/vaccines8030534","article-title":"Vaccination into the Dermal Compartment: Techniques, Challenges, and Prospects","volume":"8","author":"Hettinga","year":"2020","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"10.1016\/j.vaccine.2022.04.067_b0045","doi-asserted-by":"crossref","first-page":"e2035693","DOI":"10.1001\/jamanetworkopen.2020.35693","article-title":"Immunogenicity and Safety of Reduced-Dose Intradermal vs Intramuscular Influenza Vaccines: A Systematic Review and Meta-analysis","volume":"4","author":"Egunsola","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2022.04.067_b0050","doi-asserted-by":"crossref","unstructured":"World Health Organization. Polio vaccines: WHO position paper, March 2016-recommendations. Vaccine 2017;35:1197-9. https:\/\/doi.org\/10.1016\/j.vaccine.2016.11.017.","DOI":"10.1016\/j.vaccine.2016.11.017"},{"key":"10.1016\/j.vaccine.2022.04.067_b0055","unstructured":"World Health Organization. WHO Expert Consultation on Rabies. Second report. World Health Organ Tech Rep Ser 2013:1-139, back cover."},{"key":"10.1016\/j.vaccine.2022.04.067_b0060","doi-asserted-by":"crossref","unstructured":"World Health Organization. Rabies vaccines: WHO position paper, April 2018 - Recommendations. Vaccine 2018;36:5500-3. https:\/\/doi.org\/10.1016\/j.vaccine.2018.06.061.","DOI":"10.1016\/j.vaccine.2018.06.061"},{"key":"10.1016\/j.vaccine.2022.04.067_b0065","doi-asserted-by":"crossref","unstructured":"Roozen GVT, Prins MLM, van Binnendijk R, Hartog Gd, Kuiper VP, Prins C, et al. Tolerability, safety and immunogenicity of intradermal delivery of a fractional dose mRNA-1273 SARS-CoV-2 vaccine in healthy adults as a dose sparing strategy. medRxiv 2021:2021.07.27.21261116. https:\/\/doi.org\/10.1101\/2021.07.27.21261116.","DOI":"10.1101\/2021.07.27.21261116"},{"issue":"12","key":"10.1016\/j.vaccine.2022.04.067_b0070","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.3390\/vaccines9121375","article-title":"Immunogenicity and Safety of an Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthy Population","volume":"9","author":"Intapiboon","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2022.04.067_b0075","doi-asserted-by":"crossref","first-page":"990","DOI":"10.3390\/vaccines9090990","article-title":"Intradermal ChAdOx1 Vaccine Following Two CoronaVac Shots: A Case Report","volume":"9","author":"Singhatiraj","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2022.04.067_b0080","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1016\/j.vaccine.2008.03.095","article-title":"Intradermal vaccine delivery: will new delivery systems transform vaccine administration?","volume":"26","author":"Lambert","year":"2008","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2022.04.067_b0085","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/s41591-020-0913-5","article-title":"A serological assay to detect SARS-CoV-2 seroconversion in humans","volume":"26","author":"Amanat","year":"2020","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.vaccine.2022.04.067_b0090","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","article-title":"Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection","volume":"27","author":"Feng","year":"2021","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.vaccine.2022.04.067_b0095","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/s41587-020-0631-z","article-title":"A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction","volume":"38","author":"Tan","year":"2020","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.vaccine.2022.04.067_b0100","unstructured":"U.S. Department of Health and Human Services (FDA). Guidance for Industry Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials September 2007 [Available from: https:\/\/www.fda.gov\/media\/73679\/download. Accessed date 30 November, 2021."},{"key":"10.1016\/j.vaccine.2022.04.067_b0105","doi-asserted-by":"crossref","first-page":"101868","DOI":"10.1016\/j.tmaid.2020.101868","article-title":"Fractional dose of intradermal compared to intramuscular and subcutaneous vaccination - A systematic review and meta-analysis","volume":"37","author":"Schnyder","year":"2020","journal-title":"Travel Med Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2022.04.067_b0110","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41577-021-00625-9","article-title":"T cell-oriented strategies for controlling the COVID-19 pandemic","volume":"21","author":"Noh","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2022.04.067_b0115","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.645210","article-title":"Vaccine Inoculation Route Modulates Early Immunity and Consequently Antigen-Specific Immune Response","volume":"12","author":"Rosenbaum","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2022.04.067_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2019.112715","article-title":"Multiplex analysis of antigen-specific memory B cells in humans using reversed B-cell FluoroSpot","volume":"478","author":"Jahnmatz","year":"2020","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.vaccine.2022.04.067_b0125","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.740708","article-title":"Evidence of SARS-CoV-2-Specific Memory B Cells Six Months After Vaccination With the BNT162b2 mRNA Vaccine","volume":"12","author":"Ciabattini","year":"2021","journal-title":"Front Immunol"},{"issue":"281\u201395","key":"10.1016\/j.vaccine.2022.04.067_b0130","article-title":"Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6\u20138 months after the infection","volume":"2","author":"Sherina","year":"2021","journal-title":"Med (N Y)"},{"issue":"32","key":"10.1016\/j.vaccine.2022.04.067_b0135","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.1016\/j.vaccine.2020.05.054","article-title":"Immunogenicity and safety of two-visit, intradermal pre-exposure rabies prophylaxis simultaneously administrated with chimeric live-attenuated Japanese encephalitis vaccine in children living in rabies and Japanese encephalitis endemic country","volume":"38","author":"Angsuwatcharakon","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.04.067_b0140","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1007\/s00105-002-0367-3","article-title":"BCG ulcer. Rapid healing with topical INH powder","volume":"53","author":"Fritz","year":"2002","journal-title":"Hautarzt"},{"key":"10.1016\/j.vaccine.2022.04.067_b0145","first-page":"94","article-title":"Comparison of intradermal and intramuscular administration of hepatitis B vaccine in neonates","volume":"20","author":"Lankarani","year":"2001","journal-title":"Indian J Gastroenterol"},{"issue":"10249","key":"10.1016\/j.vaccine.2022.04.067_b0150","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.04.067_b0155","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/nm.3409","article-title":"Key roles of adjuvants in modern vaccines","volume":"19","author":"Reed","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2022.04.067_b0160","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13031-021-00404-2","article-title":"Sanctioned countries in the global COVID-19 vaccination campaign: the forgotten 70","volume":"15","author":"Blanchet","year":"2021","journal-title":"Confl Health"},{"issue":"42","key":"10.1016\/j.vaccine.2022.04.067_b0165","doi-asserted-by":"crossref","first-page":"6256","DOI":"10.1016\/j.vaccine.2021.09.019","article-title":"Inequalities in coverage of COVID-19 vaccination: A population register based cross-sectional study in Wales","volume":"39","author":"Perry","year":"2021","journal-title":"UK Vaccine"},{"key":"10.1016\/j.vaccine.2022.04.067_b0170","doi-asserted-by":"crossref","DOI":"10.1590\/1980-549720210041","article-title":"Low COVID-19 vaccination coverage and high COVID-19 mortality rates in Brazilian elderly","volume":"24","author":"Kupek","year":"2021","journal-title":"Rev Bras Epidemiol"},{"key":"10.1016\/j.vaccine.2022.04.067_b0175","unstructured":"Hannah Ritchie EM, Lucas Rod\u00e9s-Guirao, Cameron Appel, Charlie Giattino, Esteban Ortiz-Ospina, Joe Hasell, Bobbie Macdonald, Diana Beltekian and Max Roser. Coronavirus Pandemic (COVID-19): Our World in Data; 2020 [cited 2021 26 sep 2021]. Available from: https:\/\/ourworldindata.org\/covid-vaccinations. Accessed date 26 September, 2021."},{"key":"10.1016\/j.vaccine.2022.04.067_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108162","article-title":"A focused review on technologies, mechanisms, safety, and efficacy of available COVID-19 vaccines","volume":"100","author":"Ghasemiyeh","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.vaccine.2022.04.067_b0185","article-title":"Intradermal covid-19 vaccination could solve supply problems","volume":"374","author":"Schweiger","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2022.04.067_b0190","doi-asserted-by":"crossref","unstructured":"Ciarambino T, Para O, Giordano M. Immune system and COVID-19 by sex differences and age. Womens Health (Lond) 2021;17:17455065211022262. https:\/\/doi.org\/10.1177\/17455065211022262.","DOI":"10.1177\/17455065211022262"},{"issue":"10","key":"10.1016\/j.vaccine.2022.04.067_b0195","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1002\/jmv.25989","article-title":"A comparison study of SARS-CoV-2 IgG antibody between male and female COVID-19 patients: A possible reason underlying different outcome between sex","volume":"92","author":"Zeng","year":"2020","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2022.04.067_b0200","doi-asserted-by":"crossref","unstructured":"Abe KT, Li Z, Samson R, Samavarchi-Tehrani P, Valcourt EJ, Wood H, et al. A simple protein-based surrogate neutralization assay for SARS-CoV-2. JCI Insight 2020;5. https:\/\/doi.org\/10.1172\/jci.insight.142362.","DOI":"10.1172\/jci.insight.142362"},{"key":"10.1016\/j.vaccine.2022.04.067_b0205","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1080\/22221751.2020.1835448","article-title":"Validation and clinical evaluation of a SARS-CoV-2 surrogate virus neutralisation test (sVNT)","volume":"9","author":"Meyer","year":"2020","journal-title":"Emerg Microbes Infect"},{"issue":"4","key":"10.1016\/j.vaccine.2022.04.067_b0210","doi-asserted-by":"crossref","first-page":"115294","DOI":"10.1016\/j.diagmicrobio.2020.115294","article-title":"Evaluation of a commercially-available surrogate virus neutralization test for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)","volume":"99","author":"Valcourt","year":"2021","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2022.04.067_b0215","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2116932119","article-title":"Testing fractional doses of COVID-19 vaccines","volume":"119","author":"Wi\u0119cek","year":"2022","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22005217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22005217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:14:04Z","timestamp":1759403644000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22005217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":43,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0264410X22005217"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.04.067","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.12.12.21267695","asserted-by":"object"}]},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and reactogenicity after booster dose with AZD1222 via intradermal route among adult who had received CoronaVac","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.04.067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}